High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses

Leukemia

Volumn 26, Issue 11, 2012, Pages 2353-2359

  MetzelDer, S K ^a   SchroeDer, T ^b   Finck, A ^c   Scholl, S ^d   Fey, M ^e   Gotze K ^f   Linn, Y C ^g   Kroger M ^h   Reiter, A ⁱ   Salih, H R ^j   Heinicke, T ^k   Stuhlmann, R ^l   Muller L ^f   Giagounidis, A ^m   Meyer, R G ⁿ   Brugger, W ^o   Vohringer M ^p   Dreger, P ^q   Mori, M ^r,s   Basara, N ^t   Schafer Eckart K ^u   Schultheis, B ^v   Baldus, C ^w   Neubauer, A ^a   Burchert, A ^a   more..

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f Technische Univerisität München ^*  (Germany)

^g SINGAPORE GENERAL HOSPITAL   (Singapore)

^h Onkologische Schwerpunktpraxis Bremerhaven   (Germany)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j UNIVERSITY OF TÜBINGEN   (Germany)

^k OTTO VON GUERICKE UNIVERSITY   (Germany)

^l DEPARTMENT OF CARDIOLOGY   (Germany)

^m ST JOHANNES HOSPITAL   (Germany)

ⁿ UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^o SCHWARZWALD BAAR KLINIKUM   (Germany)

^p ROBERT BOSCH HOSPITAL   (Germany)

^q UNIVERSITY OF HEIDELBERG   (Germany)

^r UNIVERSITY OF VERMONT   (United States)

^s SEIREI HAMAMATSU GENERAL HOSPITAL   (Japan)

^t UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^u KLINIKUM NÜRNBERG   (Germany)

^v RUHR UNIVERSITY BOCHUM   (Germany)

^w CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

FLT3 ITD; Sorafenib; Stem cell transplantation

Indexed keywords

CD135 ANTIGEN; SORAFENIB;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOIMMUNITY; ALOPECIA; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; CYTOPENIA; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HAND FOOT SYNDROME; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERTENSION; INFECTION; LEUKEMIA REMISSION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PYRIDINES; RETROSPECTIVE STUDIES;

EID: 84869090342     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.105     Document Type: Article

References (36)

1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2009; 115: 453-474.
2. Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: Still challenging after all these years. Blood 2010; 116: 5089-5102.
3. Frohling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 2002; 100: 4372-4380. (Pubitemid 35434129)
4. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
5. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335. (Pubitemid 34627197)
6. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-318.
7. Grundler R, Miething C, Thiede C, Peschel C, Duyster J. FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model. Blood 2005; 105: 4792-4799. (Pubitemid 40807305)
8. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60. (Pubitemid 40053063)
9. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for olDer patients with acute myeloid leukemia not consiDered fit for intensive chemotherapy. Blood 2006; 108: 3262-3270.
10. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669-3676. (Pubitemid 38596280)
11. Zhang W, Konopleva M, Shi YX, McQueen T, Harris D, Ling X et al. Mutant FLT3: A direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst 2008; 100: 184-198. (Pubitemid 351480557)
12. Pratz KW, Cho E, Levis MJ, Karp JE, Gore SD, McDevitt M et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia 2010; 24: 1437-1444.
13. Crump M, Hedley D, Kamel-Reid S, Leber B, Wells R, Brandwein J et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: A NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma 2010; 51: 252-260.
14. Borthakur G, Kantarjian H, Ravandi F, Zhang W, Konopleva M, Wright JJ et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias. Haematologica 2010; 96: 62-68.
15. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
16. Scholl S, Spies-Weisshart B, Klink A, Muegge LO, Fricke HJ, Hochhaus A. Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations. Ann Hematol 2011; 90: 473-475.
17. MetzelDer S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A et al. Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: Sustained regression before and after allogeneic stem cell transplantation. Blood 2009; 113: 6567-6571.
18. MetzelDer SK, Wollmer E, Neubauer A, Burchert A. Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: A novel treatment option. Dtsch Med Wochenschr 2010; 135: 1852-1856.
19. Safaian NN, Czibere A, Bruns I, Fenk R, Reinecke P, Dienst A et al. Sorafenib (Nexavar((R))) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD acute myeloid leukemia. Leuk Res 2009; 33: 348-350.
20. Lee SH, Paietta E, Racevskis J, Wiernik PH. Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation. Am J Hematol 2009; 84: 701-702.
21. SchroeDer T, Zohren F, Saure C, Bruns I, Czibere A, Safaian NN et al. Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy. Acta Haematol 2010; 124: 153-159.
22. Mori M, Sprague J. The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics. Leuk Res 2011; 36: E1-e3.
23. Mohan BP, How GF, Loh Y, Linn YC. Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia. Br J Haematol 2012; 157: 131-132.
24. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642-4649. (Pubitemid 46594039)
25. Rollig C, Brandts C, Shaid S, Hentrich M, Kramer A, Junghanss C et al. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. Leuk Lymphoma 2011; e-pub ahead of print 7 December 2011; doi:10.3109/10428194.2011.637210.
26. Fischer T, Stone RM, Deangelo DJ, Galinsky I, Estey E, Lanza C et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and highrisk myelodysplastic syndrome with either wild-type or mutated FLT3. J Clin Oncol 2010; 28: 4339-4345.
27. Cortes JE, Perl AE, Smith CC, Kovacsovics T, Dombret H, Dohner H et al. A phase II open-label, Ac220 monotherapy efficacy study in patients with refractory/relapsed Flt3-Itd positive acute myeloid leukemia: Updated interim results. ASH Annu Meet Abstr 2011; 118: 2576.
28. Ravandi F, Cortes JE, Jones D, FaDerl S, Garcia-Manero G, Konopleva MY et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol 2010; 28: 1856-1862.
29. Serve H, Wagner R, Sauerland C, Brunnberg U, Krug U, Schaich M et al. Sorafenib in combination with standard induction and consolidation therapy in elDerly AML patients: Results from a randomized placebo-controlled phase II trial. ASH Annu Meet Abstr 2010; 116: 333.
30. Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood 2011; 117: 3294-3301.
31. Sato T, Yang X, Knapper S, White P, Smith BD, Galkin S et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 2011; 117: 3286-3293.
32. Winkler J, Rech D, Kallert S, Rech J, Meidenbauer N, Roesler W et al. Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: A case report. Leuk Res 2010; 34: E270-e272.
33. Sora F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Laurenti L et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD) acute myeloid leukemia after allogenic stem cell transplantation. Leuk Res 2011; 35: 422-423.
34. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, LedDerose G, Wassmann B et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: Results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23: 7583-7593. (Pubitemid 46291822)
35. Yokoyama H, Lundqvist A, Su S, Childs R. Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood 2010; 116: 2858-2859.
36. Sharma M, Ravandi F, Bayraktar UD, Chiattone A, Bashir Q, Giralt S et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. Biol Blood Marrow Transplant 2011; 17: 1874-1877.